The Cost Of Stupid Is Less Than The Cost Of Bribery And Corruption

by Thomas Fox
Contact

After the butt-slide play, you might think that the sad sack Houston Astros could not sink even lower but I guess setting the Major League Baseball (MLB) record for the worst record for three straight years is not enough. Yesterday, as reported by Sam Gardner in Fox Sports Online, in a post entitled “Buzz: Astros botch Ladies Night”, the Astros managed to insult over 50% of the population with the following promotion sent out by Twitter,

9/27 is Ladies Night by @StateFarm! Ladies can learn about baseball, enjoy music, food, drinks & more! For info & tix http://www.astros.com/ladies

The Astros, teaching anyone about baseball? Really? Here are some of the tweets back in response:

Yvette Betancourt  @Yvetteab

@astros implying women don’t know about baseball?

Christie @ATXChristina

@astros @StateFarm eff both of you. Baseball was the first game I learned about as a kid. Used to keep score at games. #Misogyny

Patrick Monaghan @pkmonaghan

#Astros tweets from 1950? I learned baseball scorekeeping FROM MY MOTHER. My wife has seen more games than you. Jesus. @astros @StateFarm

And my personal favorite:

Hunter Felt @HunterFelt

@scATX What’s worse? The assumption that women would need to be taught about baseball or the idea that the @astros could do so?

Unfortunately, the Astros can only increase the cost of being so idiotic. But it did make me wonder what might be some of the costs of allegations of bribery and corruption? For the British company, GlaxoSmithKline PLC (GSK) apparently it means a big hit on sales in its Chinese operations since the story broke about its alleged corruption of Chinese medical services professionals, this past summer. In an article in the Financial Times (FT), entitled “GlaxoSmithKline China sales face growing pressure”, reporters Andrew Jack, Patrick Jenkins and David Oakley, noted that sales of the company’s products in China had dropped over 30% since the publication of the original allegations. They also reported that “As the Chinese authorities have expanded corruption and pricing probes into western and domestic drug companies since July, analysts have forecast slowed growth for the industry after a long period of expansion driven by extended medical cover and marketing to a rising middle class.” They quoted Andrew Baum, a pharmaceutical analyst with Citi, who said that “indications from his latest research suggested an absolute drop in revenues as a result of manufacturers “suspending activities” and “hospitals that are wary” of talking to drug companies following the clampdown.” While Baum “expected GSK to suffer the greatest impact, but predicted other multinational pharmaceutical companies would also report absolute sales declines in China of 10-20 per cent.”

In another FT article, entitled “Bribery fears infect drug dealings in China”, by Andrew Jack and Patti Waldmeir, they highlighted some of the current allegations against western pharmaceutical companies as explained in the bribery box score below: 

Company Amount of Alleged Bribe Source of Allegation Bribery Scheme
GSK $500MM Chinese police investigation Use of intermediaries, travel agencies to bribe doctors
Eli Lilly $4.9MM Former employee Kickbacks to doctors to prescribe the company’s products
Sanofi $277K Whistleblower Bribes paid to doctors described as research grants
Novartis $8200 Company sales rep Payments to 200 hospitals for non-existent post-trial surveys

However, there are more, and perhaps even greater, costs associated with bribery and corruption; those of which can be effected upon the population of a country where the bribery occurs. As the Foreign Corrupt Practices Act (FCPA) is a supply side-focused law, we here in the US compliance community usually try to point out the costs to businesses which engage in bribery and corruption, such as the drop in sales experienced by GSK. Jack and Waldmeir pointed to the costs for those in China where bribery in the health care industry is alleged to have occurred. The article discussed three different allegations of corruption and how they all have potentially devastating effects.

Fake Clinical Trials

The article pointed to one set of allegations which involved “multi-nationals conducting “phase IV” clinical trials”. These trials are performed after a drug is approved and “which critics claim are often for marketing purposes.” The corruption involved a third party to the companies involved who “filled out fake “clinical research forms” on trials which never took place.” Under this scenario, doctors were on record for participating in the trials but never actually participated because there were no such trials. Subsequently, any results which were claimed had no basis in fact.

Commissions for Prescriptions

Another scheme highlighted was commission payments to doctors for one company’s pharmaceutical products prescribed to patients. While the medical student attempted to backtrack by saying the doctors would only prescribe one drug over another similar drug if they received ‘commissions’; such waffling misses the entire point. The recommendation was made based upon the self-interest of the doctor in receiving the commission and not based upon the needs of the patients.

Infant Formula

In one of the worst examples of the effects of corruption, in 2008, thousands of Chinese infants became sick after drinking tainted baby milk which had been sold as safe for consumption. In response to this horrific event, “middle-class parents will go to any length to buy imported formula which they think is safe.” Moreover, “doctors and nurse often urge parents to start their newborns on formula, right from the maternity ward.” Unfortunately the Chinese media have alleged that “medical staff has been bribed to favor one brand over another”.

Entering into this imbroglio, is the French company Groupe Danone, which professed that it was “shocked” at such allegations aimed towards them, when the Chinese state television aired allegations that the “company bribed doctors and nurses to recommend its brand.” The national television company quoted a company manager who said that “the company pays hundreds of Yuan each year to bribe staff in Tianjin hospitals to feed newborns” the company’s brand. This bribery scheme extended past doctors to include nurses as well; both of whom received monthly incentive payments to use and recommend the company’s product.

Yet these allegations of wide-spread bribery and corruption are having other effects as well. Jack and Waldmeir cited to Marc de Garidel, chief executive of Ipsen SA, who said that some western companies have stopped doing promotions in China altogether. Obviously there is more and greater scrutiny by Chinese officials on not only western companies but Chinese health care providers as well; to the point that de Garidel said that in some areas, doctors did not even want to meet with pharmaceutical company representatives. Furthermore, and always omnipresent is the possibility of joint prosecutions by other national jurisdictions such as the US under the FCPA or UK government under the Bribery Act.

Another interesting effect has been on recruiting and hiring for western company’s Chinese operations. Jack and Waldmeir cited to Gregory Lovas, a corporate recruiter in the life science industry with CTPartners, who said that in the past “companies had seen China postings as a way of exposing their future leaders to an expanding market as now seeking greater existing “language, cultural understanding and market knowledge.” Lovas also said that for middle-managers his clients want “background checks and references stretching back as far as 10 years.”

As Forest Gump might say, “Stupid is as stupid does.” I wonder just how many more stupid mistakes the Astros can make this year. After all, there were only four days left in their 2013 season. As for bribery and corruption in China, the outlook is more long term. Deutsche Bank predicted that corruption investigations could well be “longer and larger” than originally thought. Or as Bette Davis intoned, if you are doing business in China, you had better fasten your seatbelt. It is going to be a bumpy ride.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Thomas Fox, Compliance Evangelist | Attorney Advertising

Written by:

Thomas Fox
Contact
more
less

Compliance Evangelist on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.